Notice Number: NOT-CA-08-004
Release Date: December 12, 2007
National Cancer Institute (NCI) (http://www.nci.nih.gov)
The National Cancer Institute (NCI) is requesting project proposals for access to NCI-sponsored resources provided by the Rapid Access to Intervention Development (RAID) Program (http://dtp.nci.nih.gov/). The RAID Program makes available to academic investigators the preclinical development resources managed by the NCI's Developmental Therapeutics Program (DTP). Access to these resources is granted on a competitive basis following the evaluation of submitted project proposals by an external review committee. However, RAID is not a grant program.
Approved projects will gain access to the drug development contract resources that are managed by DTP staff members. The goal of the RAID Program is the rapid transition of novel molecules and concepts from the laboratory level to the clinic for proof-of-principle clinical trials. The scientific priority of the RAID Program is on areas with disproportionate unmet needs such as:
The RAID Program will assist investigators who submit successful project proposals by providing any (or all) of the preclinical development steps that may be obstacles to clinical translation. Possible tasks may include: drug candidate production; bulk supply; good manufacturing process (GMP) certification; formulation; and toxicology. Suitable agents for RAID include small molecules and biological therapeutic agents (including vaccines).
There are two windows of opportunity per year to file requests for RAID support. The first window of opportunity will open on January 1 and end on February 1, 2009, at 5:00 p.m. EST. All RAID proposals must be filed electronically using a dedicated secure web site managed by the NCI DTP (for details and instructions please see http://dtp.nci.nih.gov/docs/raid/raid-es.html). Paper copies of RAID proposals will not be accepted via any means of delivery. Since RAID proposals ARE NOT grant applications, they ARE NOT processed by the Center for Scientific Review (CSR).
Inquiries regarding this Notice may be directed to:
Office of Associate Director
Developmental Therapeutics Program
Division of Cancer Treatment and Diagnosis
National Cancer Institute
6130 Executive Boulevard, EPN Suite 8022, MSC 7458
Bethesda, MD 20892-7458
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Office of Extramural
National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
Department of Health
and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.